1. Home
  2. Analysis
  3. Evista
  4. Lac-hydrin

Evista and Lac-hydrin drug interactions - a phase IV clinical study of FDA data

Summary:

The phase IV clinical study analyzes what interactions people have when they take Evista and Lac-hydrin. It is created by eHealthMe based on reports of 4 people who take the same drugs from the FDA, and is updated regularly.

What is Evista?

Evista has active ingredients of raloxifene hydrochloride. It is often used in osteoporosis. eHealthMe is studying from 25,891 Evista users. Check the latest studies of Evista.

What is Lac-hydrin?

Lac-hydrin has active ingredients of ammonium lactate. eHealthMe is studying from 534 Lac-hydrin users. Check the latest studies of Lac-hydrin.

On Jul, 21, 2026

4 people who take Evista and Lac-hydrin together, and have interactions are studied.

Evista and Lac-hydrin drug interactions.

What are the common drug interactions of Evista and Lac-Hydrin, by gender? *:

female:

  1. Depression
  2. Arteriosclerosis coronary artery (thickening and hardening of arteries- coronary artery)
  3. Sleep disorder
  4. Ischaemic stroke (stroke; caused by an interruption in the flow of blood to the brain)
  5. Metrorrhagia (uterine bleeding at irregular intervals)
  6. Arteriosclerosis (thickening and hardening of arteries)
  7. Breakthrough pain
  8. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  9. Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
  10. Menstrual disorder (disease of menstrual cycle)

male:

n/a

What are the common drug interactions of Evista and Lac-Hydrin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Breakthrough pain
  2. Muscle spasms (muscle contraction)
  3. Sleep disorder

60+:

  1. Arteriosclerosis coronary artery (thickening and hardening of arteries- coronary artery)
  2. Depression
  3. Ischaemic stroke (stroke; caused by an interruption in the flow of blood to the brain)
  4. Metrorrhagia (uterine bleeding at irregular intervals)

* Approximation only. Some reports may have incomplete information.

Do you take Evista and Lac-hydrin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Evista and Lac-hydrin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Evista:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Lac-hydrin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Evista and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lac-hydrin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on raloxifene hydrochloride and ammonium lactate (the active ingredients of Evista and Lac-hydrin, respectively), and Evista and Lac-hydrin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.